Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

• DOI: 10.1126/scitranslmed.aaa4691
• Publication Date: 2015-03-18T20:30:28Z
• Authors: Siwen Hu-Lieskovan; Stephen Mok; Blanca Homet Moreno; Jennifer Tsoi; Lidia Robert; Lucas Goedert; Elaine M. Pinheiro; Richard C. Koya; Thomas G. Graeber; Begoña Comin-Anduix; Antoni Ribas
• Keywords: Proto-Oncogene Proteins B-raf; 570; Skin Neoplasms; Cell Survival; Pyridones; Oncology and Carcinogenesis; Immunology; Programmed Cell Death 1 Receptor; Medical biotechnology; Antineoplastic Agents; Mice, Transgenic; Pyrimidinones; Inbred C57BL; Medical and Health Sciences; Transgenic; Cell Line; Vaccine Related; Major Histocompatibility Complex; Mice; Antigens, Neoplasm; Cell Line, Tumor; Oximes; Animals; Humans; CTLA-4 Antigen; Antigens; Melanoma; Protein Kinase Inhibitors; Cancer; Tumor; Biomedical and Clinical Sciences; Imidazoles; Biological Sciences; MAP Kinase Kinase Kinases; 3. Good health; Mice, Inbred C57BL; 5.1 Pharmaceuticals; 6.1 Pharmaceuticals; Neoplasm; Immunization; Immunotherapy; Development of treatments and therapeutic interventions; Biomedical engineering; Biotechnology

MEK inhibition enhanced the antitumor activity of combined BRAF inhibition and immunotherapy.